Skip to main content
. 2019 May 6;116(23):11428–11436. doi: 10.1073/pnas.1902651116

Fig. 4.

Fig. 4.

Androgen receptor alterations and outcome. (A) AR splice variant landscape. LBD, ligand binding domain. (B) AR pathway expression score in AR-amplified (n = 168) versus nonamplified (n = 159) tumors. ***P < 0.001. (C) AR amplification frequency in ARSI-naive versus exposed tumors. (D) Kaplan–Meier analysis showing time on treatment with a first-line ARSI in AR-amplified versus nonamplified tumors. (E) Association between ARV7 expression and time on treatment with a first-line ARSI. o, censored event; x, off-treatment event.